Search results for " effects"

showing 10 items of 2364 documents

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Compliance to therapy with Dapoxetine in patients affected by Premature Ejaculation

2012

Introduction Premature ejaculation (PE) is a sexual dysfunction with high prevalence. According to some reports, it is present in about 20-30% of the male population. Since 2009 PE has been treated with a novel inhibitor of serotonin re-uptake, Dapoxetine, which has been reported to be specifically active for PE. Materials and Methods 59 patients have been selected among the patients affected by PE observed at the outpatient department of Urology and Andrology of the “Paolo Giaccone” University Policlinic Hospital of Palermo. Diagnosis was confirmed unequivocally in all patients, who were suitable for drug treatment and accepted to participate in the study. They were divided in 2 groups: on…

AdultMalemedicine.medical_specialtyBenzylaminespremature ejaculation dapoxetine Cytalopram compliance side effectsAdolescentGastrointestinal DiseasesMigraine DisordersComorbidityCitalopramCitalopramNaphthalenesMedication AdherenceSettore MED/24 - UrologiaDrug treatmentYoung AdultInternal medicineSurveys and QuestionnairesPremature ejaculationmedicineOutpatient clinicHumansIn patientPremature EjaculationEiaculazione precoce dapoxetina citalopram compliance effetti collateraliLife StyleAgedGynecologyHigh prevalencebusiness.industryGeneral MedicineMiddle AgedPatient Acceptance of Health CareDapoxetineSexual dysfunctionmedicine.symptomNervous System DiseasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.

2020

Abstract Purpose The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) patients’ cohort. Materials and methods Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on the treatment modalities. Results There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic granulomatosis with polyangiitis (EGPA; 16.3%). The mean ag…

AdultMalemedicine.medical_specialtyCyclophosphamideDrug-Related Side Effects and Adverse ReactionsAzathioprineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicineAzathioprinemedicineHumansTreatment complications030212 general & internal medicineRegistriesAdverse effectCyclophosphamideGlucocorticoidsANCA associated vasculitisRetrospective Studiesbusiness.industryVasculitis registryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival RateMethotrexate030220 oncology & carcinogenesisCohortRituximabDrug Therapy CombinationFemalePolandMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessRituximabVasculitis treatmentImmunosuppressive Agentsmedicine.drugFollow-Up StudiesAdvances in medical sciences
researchProduct

Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry

2020

Abstract Background and Aims Although commonly used in inflammatory bowel disease [IBD], thiopurines frequently cause intolerance, and switching to a second thiopurine has only been reported in some small series. Ours aims in this study were to evaluate the safety of switching to a second thiopurine in a large cohort, and to assess the impact of age on tolerance. Methods Adult IBD patients from the ENEIDA registry, who were switched to a second thiopurine due to adverse events [excluding malignancies and infections], were identified. At the beginning of thiopurine treatment, patients were divided by age into two groups: 18–50 and over 60 years of age. The rate and concordance of adverse eve…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsConcordanceInflammatory bowel diseaseelderly03 medical and health sciences0302 clinical medicineinflammatory bowel diseaseInternal medicineAzathioprinemedicineHumans030212 general & internal medicinePractice Patterns Physicians'Adverse effectThiopurine elderly inflammatory bowel diseaseAgedThiopurine methyltransferasebiologyThiopurinebusiness.industryDrug SubstitutionMercaptopurineGastroenterologyAge FactorsGeneral MedicineOdds ratioDrug Tolerancemedicine.diseaseInflammatory Bowel DiseasesConfidence intervaldigestive system diseasesClinical PracticeSpainbiology.proteinAcute pancreatitis030211 gastroenterology & hepatologyFemaleRisk AdjustmentDrug MonitoringbusinessImmunosuppressive Agents
researchProduct

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

2018

Background Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859 ) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506 ). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-def…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsExacerbationInjections Subcutaneous[SDV]Life Sciences [q-bio]ImmunologyEosinophilic asthmaAntibodies Monoclonal HumanizedPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodSurveys and QuestionnairesInternal medicineEosinophiliamedicineHumansImmunology and AllergyIn patientAnti-Asthmatic Agents030212 general & internal medicineAdverse effectRespiratory Tract InfectionsComputingMilieux_MISCELLANEOUSAsthmabusiness.industryMiddle Agedmedicine.diseaseAsthma3. Good healthEosinophils[SDV] Life Sciences [q-bio]Treatment Outcome030228 respiratory systemAsthma Control QuestionnaireBronchitisFemaleInterleukin-5businessMepolizumabmedicine.drug
researchProduct

Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital

2015

Drug-induced agranulocytosis is a rare haematological disorder considered as severe adverse drug reaction. Due to its low incidence, the number of studies are low and the variability of clinical features and presentation in hospitalized patients is rarely described. Awe performed an observational, transversal and retrospective study in the haematology and toxicology unit in a tertiary hospital located in Spain (Valencia) (1996–2010) in order to assess its incidence, the drugs involved, the management and outcomes of drug-induced agranulocytosis. Twenty-one cases of agranulocytosis were retrieved. All of them presented severe and symptomatic agranulocytosis (fever and infection). The most c…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsItraconazoleHealth Toxicology and Mutagenesis030204 cardiovascular system & hematologyToxicologyTertiary Care CentersLeukocyte Count03 medical and health sciences0302 clinical medicineSulfasalazineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseMetamizoleSpainAbsolute neutrophil countFemalebusinessCefuroximeAdverse drug reactionAgranulocytosismedicine.drugHuman & Experimental Toxicology
researchProduct

Is somatosensory amplification a risk factor for an increased report of side effects? Reference data from the German general population

2015

Abstract Objective The study investigates the association between somatosensory amplification and the reporting of side effects. It establishes a German version of the Somatosensory Amplification Scale and examines its psychometric properties in a representative sample of the German population. Methods Sample size was 2.469, with 51% taking any medication. Participants answered the Somatosensory Amplification Scale, Generic Assessment of Side Effects Scale, and indicated whether they were taking any medication and the type of medication. Correlational analysis and binary logistic regression were performed. Results When examining a subsample reporting both medication intake and general bodil…

AdultMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPsychometricsPsychometricsNoceboPopulationAudiologySomatosensory systemLogistic regressionRisk FactorsGermanymedicineHumansRisk factoreducationPsychiatryeducation.field_of_studySomatosensory amplificationSomatosensory CortexMiddle AgedPsychiatry and Mental healthClinical PsychologySample size determinationFemalePsychologyJournal of Psychosomatic Research
researchProduct

Kinematic analysis of motor strategies in frail aged adults during the Timed Up and Go: how to spot the motor frailty?

2015

Asma Hassani,1 Alexandre Kubicki,2,3 Vincent Brost,1 France Mourey,2,4 Fan Yang1 1Laboratoire LE2I CNRS 6306, Université de Bourgogne, Dijon, France; 2Institut National de la Santé et de la Recherche Médicale (INSERM), Cognition Action et Plasticité Sensori-Motrice, Campus Universitaire, Université de Bourgogne, Dijon, France; 3Centre Hospitalier Universitaire de Dijon, Hôpital de Champmaillot, Dijon, France; 4Faculté de Médecine, Université de Bourgogne, Dijon, France Objective: The purpose of this work was to analyze and compare the movement kinematics of sit-to-stand (STS) and back-to-sit (B…

AdultMalemedicine.medical_specialtyFrail ElderlyMovementKinematicsTimed Up and Go testTimed Up and Go testsarcopeniaYoung AdultPhysical medicine and rehabilitationElderly persons[ INFO.INFO-BI ] Computer Science [cs]/Bioinformatics [q-bio.QM]fallsmedicineHumansFrail elderlyalzheimers-diseaseOriginal ResearchriskAged 80 and overfrailty effectsWork (physics)agingAge FactorsGeneral Medicinedwelling older-adultsmobilityBiomechanical Phenomenakinematicselderly personsClinical Interventions in AgingPhysical therapyFemaleGeriatrics and Gerontology[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]Psychologyhuman activitiesTimed up and go
researchProduct

Natalizumab: a country-based surveillance program

2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, and a demonstrated efficacy in decreasing the frequency of relapses and progression of disability in relapsing-remitting multiple sclerosis (RR MS). After the approval of FDA and EMEA in MS cases unresponsive to immunomodulating therapy or in severe MS patients also not previously treated with interferons, and considering the concern on the possible side effects, an accurate program of surveillance was organized in our country by a combined effort of AIFA, Cineca, Department of Pharmacology of University of Bologna, and a group of neurologists appointed by the National Society of Neurology (S…

AdultMalemedicine.medical_specialtyNeurologyDatabases FactualDrug-Related Side Effects and Adverse ReactionsNational Health ProgramsDrug ResistanceDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabInternal medicineOutcome Assessment Health CareMultiple SclerosiPharmacovigilanceProduct Surveillance PostmarketingmedicineAdverse Drug Reaction Reporting SystemsHumansImmunologic FactorsMULTIPLE SCLEROSISNATALIZUMABClinical Trials as Topicbusiness.industryMultiple sclerosisAntibodies MonoclonalMean ageGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyREGISTRYPHARMACOVIGILANCEPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessPreviously treatedFollow-Up Studiesmedicine.drug
researchProduct

Farm-related exposures and childhood brain tumours in seven countries: results from the SEARCH International Brain Tumour Study.

2003

A total of 1218 cases of childhood brain tumours (CBT) and 2223 control subjects from the general population were included in a population-based case-control study conducted in nine centres in seven countries. Mothers were asked about farm- or agriculture-related exposures. Significantly elevated odds ratios (OR) for CBT were associated with children's personal and maternal prenatal exposure while living on a farm with pigs (child OR = 1.7, mother OR = 2.3), horses (child OR = 1.6, mother OR = 1.8), dogs (child OR = 1.5, mother OR = 1.5) and cats (child OR = 1.5, mother OR = 1.7). Children who were exposed to pigs, horses and cats combined, while living on a farm, had a threefold elevated O…

AdultMalemedicine.medical_specialtyPediatricsAdolescentEpidemiologySwinePopulationDogsPregnancyEnvironmental healthmedicineOdds RatioAnimalsHumansNeuroectodermal Tumors PrimitiveHorseseducationChildPrenatal exposurePregnancyeducation.field_of_studybusiness.industryBrain NeoplasmsPublic healthCase-control studyAgricultureOdds ratioEnvironmental exposureEnvironmental Exposuremedicine.diseaseControl subjectsAnimals DomesticCase-Control StudiesChild PreschoolPrenatal Exposure Delayed EffectsPediatrics Perinatology and Child HealthCatsCattleFemalebusinessAgrochemicalsPaediatric and perinatal epidemiology
researchProduct